title: A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
abstract: The use of a bi-specific antibody (BsAb) is an attractive and specific approach to cancer therapy. We have constructed a fully human recombinant single chain Fv BsAb against CD19 and CD3 that was an effective treatment in an animal model of non-Hodgkin's lymphoma (NHL). The CD19/CD3 BsAb was expressed in CHO cells and purified by Ni-column chromatography. Flow cytometry revealed that the CD19/CD3 BsAb specifically bound to both CD19 and CD3-positive cells. In vitro, the CD19/CD3 BsAb could stimulate T cell proliferation and induce the lysis of cultured Raji cells in the presence of unstimulated T lymphocytes. In vivo, the CD19/CD3 BsAb efficiently inhibited tumour growth in SCID mice of NHL, and the survival time of the mice was significantly prolonged. Therefore, our CD19/CD3 BsAb is a useful tool that could be a suitable candidate for treatment of NHL.
authors.affiliation: State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Keyuan Road 4, Chengdu 610041, Sichuan, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhou
authors.forename: Lan-Tu
authors.initials: LT
authors.lastname: Gou
authors.forename: Bo
authors.initials: B
authors.lastname: Mu
authors.forename: Wei-Chan
authors.initials: WC
authors.lastname: Liao
authors.forename: Jing
authors.initials: J
authors.lastname: He
authors.forename: Cong
authors.initials: C
authors.lastname: Ma
authors.forename: Yu-Qin
authors.initials: YQ
authors.lastname: Yao
authors.forename: Jin-Liang
authors.initials: JL
authors.lastname: Yang
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D018941:Antigens, CD19 / Q000276:immunology*; D017252:CD3 Complex / Q000276:immunology*; D016466:CHO Cells; D049109:Cell Proliferation; D002846:Chromatography, Affinity; D006224:Cricetinae; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology*; D051379:Mice; D016513:Mice, SCID; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D017252:CD3 Complex; D011994:Recombinant Proteins